MAP2K7 and melanoma: In addition to treating disseminated metastatic disease, BRAF/MEK inhibitors may also provide an effective neoadjuvant strategy for local or regional BRAFV600E mutant melanoma, allowing surgical removal of previously inoperable melanomas [18].